Sign in with Google
bullish
Mesoblast (MSB AU): Preparing for Re-Submission of Biologics License Application for Ryoncil
360 Views19 Feb 2022 08:54
SUMMARY
- Mesoblast Ltd (MSB AU) has developed a range of late-stage product candidates derived from its first and second generation proprietary mesenchymal lineage cell therapy technology platforms.
- BLA resubmission of remestemcel-L and formal BLA submission of rexlemestrocel-L to the FDA are two near-term catalysts for Mesoblast. Latest clinical trial results should support efficacy of both the candidates.
- In November, Mesoblast completed a refinancing of its senior secured debt facility with a new $90 million five-year facility. Current funding is available for an estimated seven quarters.
Related Insights
More »Loading
Trending Collections
More »Loading
Trending Insights
More »- FnGuide Top10 Index Rebalance Preview: Big Flow in Large Cap Stocks
- Quiddity JPX-Nikkei 400 Rebal 2025: End Apr 2025 Ranks
- Horizon Robotics (9660 HK): Global Index Inclusion After April & October Lock-Ups
- Soundwill Holdings (878 HK): Wide Spread Ahead of the 23 May Scheme Vote
- DN Solutions IPO Officially Withdrawn: Background and Key Takeaways
Top Unpaywalled Insights
More »Loading
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Mesoblast (MSB AU): ‘Comparable’ Pricing for Ryoncil; US Commercialization Is Progressing28 Feb 2025
- Mesoblast (MSB AU): What Lies Ahead After FDA Approval09 Jan 2025
- Mesoblast (MSB AU): Trading Halt; Decreased Net Cash Usage in Q4; Positive Clinical Trial Results07 Aug 2022
- Mesoblast (MSB AU): Preparing for Re-Submission of Biologics License Application for Ryoncil19 Feb 2022
- Mesoblast (MSB AU): Gets Closer to FDA Approval Pathways on Positive Phase 3 Clinical Trial Data16 Nov 2021
x